Works by Vreman, Rick A.

Results: 36

Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America.

Published in:

Pan American Journal of Public Health / Revista Panamericana de Salud Pública, 2022, v. 46, p. 1, doi. 10.26633/RPSP.2022.115

By:

van der Zee, Ivar T.;
Vreman, Rick A.;
Liberti, Lawrence;
Alanis Garza, Mario

Publication type:

Article

Effects of alcohol hangover on simulated highway driving performance.

Published in:

Psychopharmacology, 2014, v. 231, n. 15, p. 2999, doi. 10.1007/s00213-014-3474-9

By:

Verster, Joris;
Bervoets, Adriana;
Klerk, Suzanne;
Vreman, Rick;
Olivier, Berend;
Roth, Thomas;
Brookhuis, Karel

Publication type:

Article

Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.

Published in:

Expert Review of Pharmacoeconomics & Outcomes Research, 2024, v. 24, n. 2, p. 181, doi. 10.1080/14737167.2023.2282680

By:

Kaló, Zoltán;
Niewada, Maciej;
Bereczky, Tamás;
Goettsch, Wim;
Vreman, Rick A;
Xoxi, Entela;
Trusheim, Mark;
Callenbach, Marcelien H E;
Nagy, László;
Simoens, Steven

Publication type:

Article

Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.

Published in:

Cost Effectiveness & Resource Allocation, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12962-022-00383-y

By:

Enzing, Joost J.;
Knies, Saskia;
Engel, Jop;
IJzerman, Maarten J.;
Sander, Beate;
Vreman, Rick;
Boer, Bert;
Brouwer, Werner B. F.

Publication type:

Article

Increasing the information provided by probabilistic sensitivity analysis: The relative density plot.

Published in:

Cost Effectiveness & Resource Allocation, 2020, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12962-020-00251-7

By:

Geenen, Joost W.;
Vreman, Rick A.;
Boersma, Cornelis;
Klungel, Olaf H.;
Hövels, Anke M.;
Ham, Renske M. T. Ten

Publication type:

Article

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.

Published in:

International Journal of Health Policy & Management, 2022, v. 11, n. 5, p. 642, doi. 10.34172/ijhpm.2020.198

By:

Vreman, Rick A.;
Bloem, Lourens T.;
van Oirschot, Stijn;
Hoekman, Jarno;
van der Elst, Menno E.;
Leufkens, Hubert G. M.;
Klungel, Olaf H.;
Goettsch, Wim G.;
Mantel-Teeuwisse, Aukje K.

Publication type:

Article

Real World Data in Health Technology Assessment of Complex Health Technologies.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.837302

By:

Hogervorst, Milou A.;
Pontén, Johan;
Vreman, Rick A.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Outlook for tuberculosis elimination in California: An individual-based stochastic model.

Published in:

PLoS ONE, 2019, v. 14, n. 4, p. 1, doi. 10.1371/journal.pone.0214532

By:

Goodell, Alex J.;
Shete, Priya B.;
Vreman, Rick;
McCabe, Devon;
Porco, Travis C.;
Barry, Pennan M.;
Flood, Jennifer;
Marks, Suzanne M.;
Hill, Andrew;
Cattamanchi, Adithya;
Kahn, James G.

Publication type:

Article

Synergy between health technology assessments and clinical guidelines for multiple sclerosis.

Published in:

CTS: Clinical & Translational Science, 2023, v. 16, n. 5, p. 835, doi. 10.1111/cts.13492

By:

Hogervorst, Milou A.;
Vreman, Rick A.;
Zawada, Anna;
Zielińska, Magdalena;
Dawoud, Dalia M.;
de Jong, Brigit A.;
Mantel‐Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.

Published in:

CTS: Clinical & Translational Science, 2021, v. 14, n. 4, p. 1566, doi. 10.1111/cts.13027

By:

Bloem, Lourens T.;
Vreman, Rick A.;
Peeters, Niels W. L.;
Hoekman, Jarno;
Elst, Menno E.;
Leufkens, Hubert G. M.;
Klungel, Olaf H.;
Goettsch, Wim G.;
Mantel‐Teeuwisse, Aukje K.

Publication type:

Article

A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics.

Published in:

European Journal of Health Economics, 2020, v. 21, n. 6, p. 845, doi. 10.1007/s10198-020-01176-x

By:

Geenen, Joost W.;
Belitser, Svetlana V.;
Vreman, Rick A.;
van Bloois, Martijn;
Klungel, Olaf H.;
Boersma, Cornelis;
Hövels, Anke M.

Publication type:

Article

Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group.

Published in:

International Journal of Technology Assessment in Health Care, 2023, v. 39, n. 1, p. 1, doi. 10.1017/S0266462323000375

By:

Hogervorst, Milou Amber;
Vreman, Rick;
Heikkinen, Inkatuuli;
Bagchi, Indranil;
Gutierrez-Ibarluzea, Inaki;
Ryll, Bettina;
Eichler, Hans-Georg;
Petelos, Elena;
Tunis, Sean;
Sapede, Claudine;
Goettsch, Wim;
Janssens, Rosanne;
Huys, Isabelle;
Barbier, Liese;
DeJean, Deirdre;
Strammiello, Valentina;
Lingri, Dimitra;
Goodall, Melinda;
Papadaki, Magdalini;
Toussi, Massoud

Publication type:

Article

The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments.

Published in:

International Journal of Technology Assessment in Health Care, 2023, v. 39, n. 1, p. 1, doi. 10.1017/S0266462323000338

By:

Vreman, Rick A.;
van Hoof, Daan;
Nachtnebel, Anna;
Daems, Joël;
van de Casteele, Marc;
Fogarty, Emer;
Adams, Roisin;
Timmers, Lonneke

Publication type:

Article

PP111 Reimbursement And Payment Models: A Survey Of Stakeholders' Current Experiences And Future Outlook Within The Dutch Policy Setting.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S76, doi. 10.1017/S0266462322002343

By:

Callenbach, Marcelien;
Vreman, Rick;
Mantel-Teeuwisse, Aukje;
Goettsch, Wim

Publication type:

Article

PP37 A Systematic Review of Machine Learning and Statistical Models For Predicting Coronary Heart Disease In Diabetic Patients.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S52, doi. 10.1017/S0266462322001799

By:

Jiu, Li;
Vreman, Rick;
Wang, Junfeng;
Mantel-Teeuwisse, Aukje;
Goettsch, Wim

Publication type:

Article

OP89 The CE-Signal, A New Simplified Health Technology Assessment Method To Determine Whether Interventions Are Cost-Effective.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S33, doi. 10.1017/S0266462322001350

By:

Huisman, Atse;
Knies, Saskia;
Timmers, Lonneke;
Enzing, Joost;
Vreman, Rick;
Vrinzen, Terry;
Tran, Ly

Publication type:

Article

OP11 Differences And Similarities In Past Health Technology Assessments In Beneluxa Initiative Countries.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S5, doi. 10.1017/S0266462322000708

By:

Vreman, Rick;
van Hoof, Daan;
Adams, Roisin;
van de Casteele, Marc;
Nachtnebel, Anna;
Timmers, Lonneke

Publication type:

Article

Understanding innovation of health technology assessment methods: the IHTAM framework.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, n. 1, p. 1, doi. 10.1017/S0266462322000010

By:

Jiu, Li;
Hogervorst, Milou A.;
Vreman, Rick A.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Addressing uncertainty in relative effectiveness assessments by HTA organizations.

Published in:

International Journal of Technology Assessment in Health Care, 2022, v. 38, n. 1, p. 1, doi. 10.1017/S026646232100177X

By:

Vreman, Rick A.;
Strigkos, George;
Leufkens, Hubert G. M.;
Schünemann, Holger J.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Understanding innovation of health technology assessment methods: the IHTAM framework.

Published in:

International Journal of Technology Assessment in Health Care, 2021, v. 38, n. 1, p. 1, doi. 10.1017/S0266462322000010

By:

Jiu, Li;
Hogervorst, Milou A.;
Vreman, Rick A.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Addressing uncertainty in relative effectiveness assessments by HTA organizations.

Published in:

International Journal of Technology Assessment in Health Care, 2021, v. 38, n. 1, p. 1, doi. 10.1017/S026646232100177X

By:

Vreman, Rick A.;
Strigkos, George;
Leufkens, Hubert G. M.;
Schünemann, Holger J.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.

Published in:

2021

By:

Eichler, Hans-Georg;
Adams, Roisin;
Andreassen, Einar;
Arlett, Peter;
van de Casteele, Marc;
Chapman, Suzannah J.;
Goettsch, Wim G.;
Martinsson, Jonathan Lind;
Llinares-Garcia, Jordi;
Nachtnebel, Anna;
Pean, Elias;
Rasi, Guido;
Reksten, Tove Ragna;
Timmers, Lonneke;
Vreman, Rick A.;
van de Vijver, Inneke;
Wenzl, Martin

Publication type:

journal article

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.

Published in:

Drug Safety, 2023, v. 46, n. 4, p. 357, doi. 10.1007/s40264-023-01279-3

By:

Ogar, Comfort K.;
Quick, Jonathan;
Gilbert, Hannah N.;
Vreman, Rick A.;
Mantel-Teeuwisse, Aukje K.;
Mugunga, Jean Claude

Publication type:

Article

Efficacy gap between phase II and subsequent phase III studies in oncology.

Published in:

British Journal of Clinical Pharmacology, 2020, v. 86, n. 7, p. 1306, doi. 10.1111/bcp.14237

By:

Vreman, Rick A.;
Belitser, Svetlana V.;
Mota, Ana T.M.;
Hövels, Anke M.;
Goettsch, Wim G.;
Roes, Kit C.B.;
Leufkens, Hubert G.M.;
Mantel‐Teeuwisse, Aukje K.

Publication type:

Article

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Published in:

Applied Health Economics & Health Policy, 2019, v. 17, n. 6, p. 883, doi. 10.1007/s40258-019-00496-1

By:

Vreman, Rick A.;
Geenen, Joost W.;
Hövels, Anke M.;
Goettsch, Wim G.;
Leufkens, Hubert G. M.;
Al, Maiwenn J.

Publication type:

Article

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations.

Published in:

Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 1, p. 136, doi. 10.1002/cpt.3252

By:

Madrid Paredes, Jorge;
Versteeg, Jan‐Willem;
Vreman, Rick A.;
Bloem, Lourens T.

Publication type:

Article

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

Published in:

Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 350, doi. 10.1002/cpt.1835

By:

Vreman, Rick A.;
Naci, Huseyin;
Goettsch, Wim G.;
Mantel‐Teeuwisse, Aukje K.;
Schneeweiss, Sebastian G.;
Leufkens, Hubert G. M.;
Kesselheim, Aaron S.

Publication type:

Article

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.

Published in:

Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 684, doi. 10.1002/cpt.1251

By:

Hövels, Anke M.;
Mantel‐Teeuwisse, Aukje K.;
Leufkens, Hubert G.M.;
Vreman, Rick A.;
Goettsch, Wim G.;
Bloem, Lourens T.;
Bouvy, Jacoline C.

Publication type:

Article

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.

Published in:

Pharmacology Research & Perspectives, 2021, v. 9, n. 2, p. 1, doi. 10.1002/prp2.742

By:

Kalf, Rachel R. J.;
Vreman, Rick A.;
Delnoij, Diana M. J.;
Bouvy, Marcel L.;
Goettsch1,2., Wim G.

Publication type:

Article

Getting the Right Evidence After Drug Approval.

Published in:

Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.569535

By:

Vreman, Rick A.;
Leufkens, Hubert G. M.;
Kesselheim, Aaron S.

Publication type:

Article

Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability: Framework and Calculation Tool to Determine the Suitability of MEAs: M.H.E. Callenbach et al.

Published in:

PharmacoEconomics, 2025, v. 43, n. 1, p. 53, doi. 10.1007/s40273-024-01433-4

By:

Callenbach, Marcelien H. E.;
Vreman, Rick A.;
Leopold, Christine;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Comment on "Deterministic Sensitivity Analysis Under Ignorance".

Published in:

2021

By:

Vreman, Rick A.;
Geenen, Joost W;
Knies, Saskia;
Mantel-Teeuwisse, Aukje K.;
Leufkens, Hubert G. M.;
Goettsch, Wim G.

Publication type:

Letter

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

Published in:

PharmacoEconomics, 2021, v. 39, n. 1, p. 1, doi. 10.1007/s40273-020-00979-3

By:

Vreman, Rick A.;
Geenen, Joost W.;
Knies, Saskia;
Mantel-Teeuwisse, Aukje K.;
Leufkens, Hubert G. M.;
Goettsch, Wim G.

Publication type:

Article

Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America.

Published in:

Pan American Journal of Public Health, 2022, v. 46, p. 1, doi. 10.26633/RPSP.2022.115

By:

van der Zee, Ivar T.;
Vreman, Rick A.;
Liberti, Lawrence;
Garza, Mario Alanis

Publication type:

Article

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.

Published in:

International Journal of Environmental Research & Public Health, 2023, v. 20, n. 1, p. 340, doi. 10.3390/ijerph20010340

By:

Callenbach, Marcelien H. E.;
Vreman, Rick A.;
Mantel-Teeuwisse, Aukje K.;
Goettsch, Wim G.

Publication type:

Article

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Published in:

International Journal of Environmental Research & Public Health, 2020, v. 17, n. 22, p. 8309, doi. 10.3390/ijerph17228309

By:

A Vreman, Rick;
F Broekhoff, Thomas;
GM Leufkens, Hubert;
K Mantel-Teeuwisse, Aukje;
G Goettsch, Wim

Publication type:

Article